Paik S, Shak S, Tang G et al.. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–2826.

• PubMed
PaikSShakSTangG. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–2826. )| false
• Search Google Scholar
• Export Citation

Van't Veer LJ, Dai H, van de Vijver MJ et al.. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530–536.

• PubMed
Van't VeerLJDaiHvan de VijverMJ. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530–536. )| false
• Search Google Scholar
• Export Citation

Sparano JA, Gray RJ, Makower DF et al.. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 2015;373:2005–2014.

• PubMed
SparanoJAGrayRJMakowerDF. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 2015;373:2005–2014. )| false
• Search Google Scholar
• Export Citation

Paik S, Tang G, Shak S et al.. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726–3734.

• PubMed
PaikSTangGShakS. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726–3734. )| false
• Search Google Scholar
• Export Citation

Cardoso F, van't Veer LJ, Bogaerts J et al.. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016;375:717–729.

• PubMed
CardosoFvan't VeerLJBogaertsJ. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016;375:717–729. )| false
• Search Google Scholar
• Export Citation

Petkov VI, Miller DP, Howlader N et al.. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. Available at: https://www.nature.com/articles/npjbcancer201617. Accessed April 11, 2017.

• PubMed
PetkovVIMillerDPHowladerN. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. Available at: https://www.nature.com/articles/npjbcancer201617. Accessed April 11, 2017. )| false
• Search Google Scholar
• Export Citation

Albain KS, Barlow WE, Shak S et al.. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55–65.

• PubMed
AlbainKSBarlowWEShakS. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55–65. )| false
• Search Google Scholar
• Export Citation

Pan H, Gray RG, Davies C et al.. Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET) [abstract]. J Clin Oncol 2016;34(Suppl):Abstract 505.

• PubMed
PanHGrayRGDaviesC. Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET) [abstract]. J Clin Oncol 2016;34(Suppl):Abstract 505. )| false
• Search Google Scholar
• Export Citation

Gradishar WJ, Anderson BO, Balassanian R et al.. NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, Version 1.2017. Accessed April 5, 2017. To view the most recent version of these guidelines, visit NCCN.org.

• PubMed
GradisharWJAndersonBOBalassanianR. NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, Version 1.2017. Accessed April 5, 2017. To view the most recent version of these guidelines, visit NCCN.org. )| false
• Search Google Scholar
• Export Citation